News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2021 Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO Michael O'Riordan May 16, 2021
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2019 Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO Michael O'Riordan April 01, 2019
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery Michael O'Riordan March 19, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017